Journals / Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi / 2021 / Cilt: 24 - Sayı: 3

SARS-COV-2: A Current Update About Miscellaneous Symptoms

SARS-COV-2: Çeşitli Belirtiler Hakkında Güncel Bir Derleme

Pages
294–298
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Inthis review, we especially focused on miscellaneous symptoms causedby virus, from the perspective of a physiatrist, besides systemic complications

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2) particle causes different clinical responses in the hostdepending on the genetic background and prolonged symptoms maydevelop after recovery.
📊
Key Findings & Data:With today's knowledge, we may describeSARS-CoV-2 infection the cause of an autoimmune viral vasculopathyclinic.
💡
Conclusion & Impact:Inthis review, we especially focused on miscellaneous symptoms causedby virus, from the perspective of a physiatrist, besides systemic complications
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2) particle causes different clinical responses in the hostdepending on the genetic background and prolonged symptoms maydevelop after recovery. With today's knowledge, we may describeSARS-CoV-2 infection the cause of an autoimmune viral vasculopathyclinic. With our current information, it is not clear which patients willdevelop severe or prolonged disease. There are many different pathophysiological mechanisms that cause coronavirus disease-2019-relatedsymptoms like chronic pain, fatigue, sarcopenia, vasculopathy, autoimmun disorders, arthritis and central sensitization etc.We now knowthat SARS-CoV-2 causes immune response and life-threatening conditions as a result of microthrombosis and endothelial dysfunction inmany vital organs. Also it triggers an immune response in the host. Thisimmun reaction may trigger autoimmune diseases in the long term. Inthis review, we especially focused on miscellaneous symptoms causedby virus, from the perspective of a physiatrist, besides systemic complications

Özet

Şiddetli akut solunum sendromu-koronavirüs-2 [severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)] partikülü, genetik zemine bağlı olarak konakta farklı klinik yanıtlara neden olur ve iyileşmeden sonra uzun süreli semptomlar gelişebilir. Günümüzün bilgisiyle, SARS-CoV-2 enfeksiyonunu bir otoimmün viral vaskülopati kliniğinin nedeni olarak tanımlayabiliriz. Mevcut bilgilerimizle hangi hastaların şiddetli veya uzun süreli hastalık geliştireceği net değildir. Kronik ağrı, yorgunluk, sarkopeni, vaskülopati, otoimmün bozukluklar, artrit ve santral sensitizasyon gibi SARS-CoV-2 ile ilişkili semptomlara neden olan birçok farklı patofizyolojik mekanizma vardır. SARS-CoV2’nin birçok hayati organda mikrotromboz ve endotel disfonksiyonunun sonucu immün yanıt ve yaşamı tehdit eden durumlara neden olduğunu artık biliyoruz. Ayrıca konakta bir immün yanıtı tetikler. Bu immün reaksiyon, uzun vadede otoimmün hastalıkları tetikleyebilir. Bu derlemede, sistemik komplikasyonların yanı sıra özellikle bir fiziyatrist bakış açısından virüsün neden olduğu çeşitli semptomlara odaklandık

🔖

Cite This Article

KOCA, T. T., SAĞIROĞLU, S. (2022). SARS-COV-2: A Current Update About Miscellaneous Symptoms. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi, Cilt: 24 - Sayı: 3, 294–298. https://ajindex.com/articles/516760

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bohn MK, Hall A, Sepiashvili L, et al. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020
  2. [Crossref] [Pubmed] [PMC] 2. Marinangeli F, Giarratano A, Petrini F. Chronic Pain and COVID-19: pathophysiological, clinical and organizational issues. Minerva Anestesiol. 2020. [Crossref] [Pubmed] 3. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020
  3. [Crossref] [Pubmed] [PMC] 4. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020
  4. [Crossref] [Pubmed] [PMC] 5. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020
  5. [Crossref] [Pubmed] [PMC] 6. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021
  6. [Crossref] [Pubmed] [PMC] 7. Matsuyama T, Kubli SP, Yoshinaga SK, et al. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020
  7. [Crossref] [Pubmed] [PMC] 8. Eriksson O, Hultström M, Persson B, et al. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020
  8. [Crossref] [Pubmed] [PMC] 9. Shrestha GS, Khanal S, Sharma S, et al. COVID-19: Current understanding of pathophysiology. J Nepal Health Res Counc. 2020
  9. [Crossref] [Pubmed] 10. Dobesh PP, Trujillo TC. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy. 2020
  10. [Crossref] [Pubmed] [PMC] 11. Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses. Curr Hypertens Rep. 2020
  11. [Crossref] [Pubmed] [PMC] 12. Santilli V, Bernetti A, Mangone M, et al. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014
  12. [Pubmed] [PMC] 13. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transittime changes, tissue hypoxia and inflammation. Physiol Rep. 2021 Feb
  13. 9(3):e14726. [Crossref] [Pubmed] [PMC] 14. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020
  14. e0240784. [Crossref] [Pubmed] [PMC] 15. Jin